Today, March 8th 2017, Medical Prognosis Institute A/S (“MPI”) announces that the company has exercised 100,000 warrants in Oncology Venture Sweden AB (“Oncology Venture”). The exercised warrants were part of the 302,243 warrants in Oncology Venture that MPI was granted in return for Oncology Venture’s extended exclusive license to the MPI Drug Response Prediction (DRPTM) technology, as communicated in a press release on 2016-12-30. The total price for the warrant exercise is about SEK 1 million. Final terms will be adjusted following dilution in the rights issue in Oncology Venture, which calls for a recalculation of warrants of series 2019 in accordance with set warrant terms. MPI has the possibility to exercise the remaining 202,243 warrants until December 31st 2019.
“The warrants strengthen the bond between MPI and Oncology Venture and contribute to the continued and aligned interest between the two companies in moving the DRP technology forward as a valuable tool for improving the treatment of cancer patients,” says Frank Knudsen, Chairman of the Board of MPI.
About MPI’s multiple biomarker called Drug Response Predictor – DRP(TM)
MPI’s DRP(TM) is a tool for developing tumor-derived genetic signatures to predict which cancer patients are high likely to respond to a given anti-cancer product. The DRP(TM) has been tested in 37 trials, where 29 trials showed that drug-specific DRP(TM) Biomarkers could predict which patients responded well to the treatment. The DRP(TM) platform has amongst others been externally validated and published in collaboration with leading statisticians at the MD Anderson Cancer Center. The DRP(TM) method can be used to design the Clinical Development Plan, i.e. to select which indications are relevant for a given anti-cancer drug. In addition to this, the individual genetic patterns of patients can be analyzed as part of a screening procedure for a clinical trial to ensure inclusion of patients with a high likelihood of response to the drug. DRP(TM) builds on comparison between sensitive and resistant human cancer cell lines, including genomic information from cell lines combined with clinical tumor biology and clinical correlates in a systems biology network. The DRP(TM) is a Big Data tool based on messenger RNA. The DRP(TM) platform can be used in all cancer types, and has been patented for more than 70 anti-cancer drugs in the US.
Medical Prognosis Institute a publicly traded international company specialized in improving cancer patients’ lives by developing Personalized Medicine using its unique DRP(TM) technology. MPI’s exceptional opportunity to personalize cancer treatment begins with Breast Cancer moving on to Multiple Myeloma and Prostate Cancer as the first steps. MPI’s DRP(TM) tool has shown its ability to separate patients who benefit and who do not benefit from a specific cancer treatment. This has been shown in as many as 29 out of 37 trials, and covers more than 80 anti-cancer treatments in a wide range of cancer indications. MPI has built a significant large database with over 1,000 screened breast cancer patients and is building up a database in Multiple Myeloma to be followed by Prostate cancer in collaboration with oncologists and hematologists throughout Denmark.
For further information, please contact:
CEO, Peter Buhl Jensen, Adjunct Professor, MD, Ph.D. Ulla Hald Buhl, IR & Communication
E-mail: firstname.lastname@example.org E-mail: email@example.com
Telephone: +45 21 60 89 22 Telephone +45 21 70 10 49
This information is information that Medical Prognosis Institute A/S is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on March 8th 2017.
Certified Advisor: Sedermera Fondkommission, Norra Vallgatan 64, 211 22, Malmö, Sweden